NCT06567704 Cancer-related Fatigue During Maintenance Immunotherapy for Non-small Cell Lung Cancer (NSCLC): a Qualitative Study
| NCT ID | NCT06567704 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wake Forest University Health Sciences |
| Condition | Non-small Cell Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-03-26 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2025-03-26 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research is to understand cancer related fatigue in patients with non-small cell lung cancer (NSCLC), who are being treated with an immune checkpoint inhibitor.
Eligibility Criteria
Inclusion Criteria: * ≥ 18 years of age at the time of consent. * Must be able to speak, read, and understand English. * Participants diagnosed with NSCLC, and: * have advanced/metastatic disease who are currently receiving immunotherapy monotherapy, or * have locally advanced disease who are currently receiving immunotherapy monotherapy after completing thoracic radiation therapy, or * who underwent resection and are currently receiving immunotherapy monotherapy after completing all other perioperative treatment * Immunotherapy planned to continue for at least three months after the time of study enrollment (to ensure participant remains on IO long enough to obtain study assessments) * Have completed at least two cycles of immunotherapy. * Self-reported cancer-related fatigued that impacts daily function. Exclusion Criteria: * Participants who have received a dose of chemotherapy (including maintenance pemetrexed) within the past 3 months * Participants who have received radiation therapy within the past 3 months. Note: a short course of palliative radiation therapy within up to 20 Gy and up to 5 fractions is permissible. * Diagnosis of dementia. * Anemia Hgb \<10 g/dL. * Sarcopenia which is being pharmacologically treated with a prescribed appetite stimulant (e.g., megestrol). * Untreated hypothyroidism. * Symptomatic heart failure. * Oxygen dependent lung disease. * Cognitively unable to complete interviews per investigator.
Contact & Investigator
Dori Beeler, PhD
PRINCIPAL INVESTIGATOR
Atrium Health Levine Cancer
Frequently Asked Questions
Who can join the NCT06567704 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Non-small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06567704 currently recruiting?
Yes, NCT06567704 is actively recruiting participants. Contact the research team at Megan.Lattanze@advocatehealth.org for enrollment information.
Where is the NCT06567704 trial being conducted?
This trial is being conducted at Charlotte, United States, Winston-Salem, United States.
Who is sponsoring the NCT06567704 clinical trial?
NCT06567704 is sponsored by Wake Forest University Health Sciences. The principal investigator is Dori Beeler, PhD at Atrium Health Levine Cancer. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.